Cargando…

Proposed morbidity markers among Schistosoma mansoni patients

BACKGROUND: Fecal calprotectin (FC) and fecal occult blood (FOB) were suggested as potential inflammatory markers for assessing intestinal schistosomiasis morbidity that are conventionally detected through invasive methods. AIM AND OBJECTIVES: The present work aimed to evaluate FC and FOB as morbidi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shehab, Amel Youssef, Allam, Amal Farahat, Saad, Awad Abd El Kader, Osman, Mervat Mostafa, Ibrahim, Heba Said, Moneer, Esraa Abdelhamid, Tolba, Mona Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321587/
https://www.ncbi.nlm.nih.gov/pubmed/37415754
http://dx.doi.org/10.4103/tp.tp_46_22
_version_ 1785068643522969600
author Shehab, Amel Youssef
Allam, Amal Farahat
Saad, Awad Abd El Kader
Osman, Mervat Mostafa
Ibrahim, Heba Said
Moneer, Esraa Abdelhamid
Tolba, Mona Mohamed
author_facet Shehab, Amel Youssef
Allam, Amal Farahat
Saad, Awad Abd El Kader
Osman, Mervat Mostafa
Ibrahim, Heba Said
Moneer, Esraa Abdelhamid
Tolba, Mona Mohamed
author_sort Shehab, Amel Youssef
collection PubMed
description BACKGROUND: Fecal calprotectin (FC) and fecal occult blood (FOB) were suggested as potential inflammatory markers for assessing intestinal schistosomiasis morbidity that are conventionally detected through invasive methods. AIM AND OBJECTIVES: The present work aimed to evaluate FC and FOB as morbidity markers of Schistosoma mansoni infection before and after praziquantel treatment. MATERIALS AND METHODS: A total of 205 stool samples (117 schoolchildren and 88 adults) were collected and examined by Kato Katz. A questionnaire enquiring about diarrhea, history of blood in stool, and abdominal pain was designed and applied. RESULTS: S. mansoni prevalence rates were 20.5% and 11.36% among children and adults, respectively; the majority of cases had light infection intensity. FC and FOB were studied among 25 cured S. mansoni cases (17 children and 8 adults) pre and one-month post treatment. Before treatment, six and four children of moderate and high S. mansoni infection intensity tested positive for FC and FOB, respectively, all turning negative after treatment. FC showed borderline statistical significance before and after treatment among children. However, all adults tested negative for FC and FOB. CONCLUSION: FC and FOB could be possibly used as morbidity monitoring tools for S. mansoni infection in children with moderate and high infection intensity.
format Online
Article
Text
id pubmed-10321587
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-103215872023-07-06 Proposed morbidity markers among Schistosoma mansoni patients Shehab, Amel Youssef Allam, Amal Farahat Saad, Awad Abd El Kader Osman, Mervat Mostafa Ibrahim, Heba Said Moneer, Esraa Abdelhamid Tolba, Mona Mohamed Trop Parasitol Original Article BACKGROUND: Fecal calprotectin (FC) and fecal occult blood (FOB) were suggested as potential inflammatory markers for assessing intestinal schistosomiasis morbidity that are conventionally detected through invasive methods. AIM AND OBJECTIVES: The present work aimed to evaluate FC and FOB as morbidity markers of Schistosoma mansoni infection before and after praziquantel treatment. MATERIALS AND METHODS: A total of 205 stool samples (117 schoolchildren and 88 adults) were collected and examined by Kato Katz. A questionnaire enquiring about diarrhea, history of blood in stool, and abdominal pain was designed and applied. RESULTS: S. mansoni prevalence rates were 20.5% and 11.36% among children and adults, respectively; the majority of cases had light infection intensity. FC and FOB were studied among 25 cured S. mansoni cases (17 children and 8 adults) pre and one-month post treatment. Before treatment, six and four children of moderate and high S. mansoni infection intensity tested positive for FC and FOB, respectively, all turning negative after treatment. FC showed borderline statistical significance before and after treatment among children. However, all adults tested negative for FC and FOB. CONCLUSION: FC and FOB could be possibly used as morbidity monitoring tools for S. mansoni infection in children with moderate and high infection intensity. Wolters Kluwer - Medknow 2023 2023-05-19 /pmc/articles/PMC10321587/ /pubmed/37415754 http://dx.doi.org/10.4103/tp.tp_46_22 Text en Copyright: © 2023 Tropical Parasitology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Shehab, Amel Youssef
Allam, Amal Farahat
Saad, Awad Abd El Kader
Osman, Mervat Mostafa
Ibrahim, Heba Said
Moneer, Esraa Abdelhamid
Tolba, Mona Mohamed
Proposed morbidity markers among Schistosoma mansoni patients
title Proposed morbidity markers among Schistosoma mansoni patients
title_full Proposed morbidity markers among Schistosoma mansoni patients
title_fullStr Proposed morbidity markers among Schistosoma mansoni patients
title_full_unstemmed Proposed morbidity markers among Schistosoma mansoni patients
title_short Proposed morbidity markers among Schistosoma mansoni patients
title_sort proposed morbidity markers among schistosoma mansoni patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321587/
https://www.ncbi.nlm.nih.gov/pubmed/37415754
http://dx.doi.org/10.4103/tp.tp_46_22
work_keys_str_mv AT shehabamelyoussef proposedmorbiditymarkersamongschistosomamansonipatients
AT allamamalfarahat proposedmorbiditymarkersamongschistosomamansonipatients
AT saadawadabdelkader proposedmorbiditymarkersamongschistosomamansonipatients
AT osmanmervatmostafa proposedmorbiditymarkersamongschistosomamansonipatients
AT ibrahimhebasaid proposedmorbiditymarkersamongschistosomamansonipatients
AT moneeresraaabdelhamid proposedmorbiditymarkersamongschistosomamansonipatients
AT tolbamonamohamed proposedmorbiditymarkersamongschistosomamansonipatients